Medilexicon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.12 M
as on 17-12-2024
- Paid Up Capital ₹ 0.12 M
as on 17-12-2024
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.50 M
as on 17-12-2024
- Revenue -33.09%
(FY 2017)
- Profit -1079.43%
(FY 2017)
- Ebitda -18.21%
(FY 2017)
- Net Worth -76.24%
(FY 2017)
- Total Assets -44.05%
(FY 2017)
About Medilexicon Pharmaceuticals
The Corporate was formerly known as Medilexicon Pharmaceticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.12 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹0.50 M.
Abhishek Verma, Shailesh Saxena, and Rohan Singhal serve as directors at the Company.
- CIN/LLPIN
U24232RJ2009PTC029111
- Company No.
029111
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jun 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medilexicon Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Verma  | Director | 10-Jun-2009 | Current |
| Shailesh Saxena | Director | 10-Jun-2009 | Current |
| Rohan Singhal | Director | 16-Jun-2016 | Current |
Financial Performance of Medilexicon Pharmaceuticals.
Medilexicon Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 33.09% decrease. The company also saw a substantial fall in profitability, with a 1079.43% decrease in profit. The company's net worth observed a substantial decline by a decrease of 76.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medilexicon Pharmaceuticals?
In 2017, Medilexicon Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Medilexicon International Industry Private LimitedActive 5 years 11 months
Rohan Singhal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 24 Mar 2014 | ₹0.50 M | Open |
How Many Employees Work at Medilexicon Pharmaceuticals?
Unlock and access historical data on people associated with Medilexicon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medilexicon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medilexicon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
